1 week Ago By Defense World Staff
Cerity Partners LLC acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,922 shares of the company’s stock, valued at approximately $40,000.
A number of other large investors have also recently made changes to their positions in ZNTL. Barclays PLC boosted its stake in shares of Zentalis Pharmaceuticals by 18.5% in the third quarter.
Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after acquiring an additional 11,748 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Zentalis Pharmaceuticals by 22.
4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock worth $1,507,000 after purchasing an additional 91,152 shares during the period.
Virtu Financial LLC purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $76,000. SG Americas Securities LLC raised its position in shares of Zentalis Pharmaceuticals by 115.6% during the fourth quarter.
SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after buying an additional 30,240 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $68,000.
Zentalis Pharmaceuticals Price PerformanceShares of NASDAQ ZNTL opened at $1.43 on Friday. The company has a market cap of $102.
69 million, a P/E ratio of -0.57 and a beta of 1.80.
The firm has a 50-day simple moving average of $1.66 and a two-hundred day simple moving average of $2.50.
Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $13.
24. Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.
66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.09.
The business had revenue of $26.90 million for the quarter. As a group, equities research analysts expect that Zentalis Pharmaceuticals, Inc.
will post -2.42 EPS for the current year. Analyst Upgrades and DowngradesA number of analysts have issued reports on the stock.
HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. Wedbush reissued a “neutral” rating and set a $4.
00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. UBS Group reduced their price objective on Zentalis Pharmaceuticals from $5.00 to $2.
20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.
00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.
com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.24.Read Our Latest Stock Report on Zentalis PharmaceuticalsInsider Transactions at Zentalis PharmaceuticalsIn related news, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, February 6th.
The shares were acquired at an average cost of $2.28 per share, with a total value of $45,600.00.
Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.
27 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jan Skvarka purchased 60,000 shares of the stock in a transaction that occurred on Friday, January 31st.
The stock was purchased at an average price of $1.72 per share, with a total value of $103,200.00.
Following the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at $257,227.72. This trade represents a 67.
00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.
60% of the company’s stock. Zentalis Pharmaceuticals Profile (Free Report)Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Featured ArticlesFive stocks we like better than Zentalis Pharmaceuticals3 Small Caps With Big Return PotentialMarkets Think Robinhood Earnings Could Send the Stock UpHow to buy stock: A step-by-step guide for beginners Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?How to Profit From Value Investing AT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundWant to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report).
.
